Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed supratentorial glioblastoma multiforme or gliosarcoma
• •Completed standard external beam radiotherapy within the past 5 weeks
• •Stable disease by MRI or CT scan
• •PATIENT CHARACTERISTICS:
• •Age
• •18 and over
• •Performance status
• •Karnofsky 60-100%
• •Life expectancy
• •More than 4 months
• •Hematopoietic
• •Absolute neutrophil count at least 1,500/mm3
• •Platelet count at least 100,000/mm3
• •No history of bleeding disorder
• •Hepatic
• •Bilirubin less than 1.5 mg/dL
• •SGPT less than 2.5 times normal
• •Alkaline phosphatase less than 2.5 times normal
• •Renal
• •BUN less than 1.5 times upper limit of normal (ULN) OR
• •Creatinine less than 1.5 times ULN
• •Cardiovascular
• •No deep vein thrombosis within the past 3 weeks (must be clinically stable)
• •Pulmonary
• •No pulmonary embolism within the past 3 weeks (must be clinically stable)
• •Other
• •Must participate in System for Thalidomide Education and Prescribing Safety program
• •No peripheral neuropathy grade 2 or greater
• •No active infection
• •No concurrent illness that may obscure toxicity or dangerously alter drug metabolism
• •No other serious concurrent illness
• •No other malignancy within the past 3 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use 2 forms of effective contraception for 1 month before, during, and for 1 month after study
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •No prior thalidomide
• •No concurrent immunotherapy
• •No concurrent prophylactic filgrastim (G-CSF)
• •Chemotherapy
• •No prior chemotherapy
• •No other concurrent chemotherapy
• •Endocrine therapy
• •No concurrent hormonal therapy
• •Concurrent corticosteroids must be at stable or decreasing dose over the past 7 days
• •Radiotherapy
• •See Disease Characteristics
• •No concurrent radiotherapy
• •Surgery
• •No concurrent surgery
• •Other
• •No other concurrent anticancer therapy
• •No other concurrent investigational agents